Infektionen durch Bacillus anthracis

W. Biederbick; R. Fock; K. Güttler; C. Veit

doi:10.1055/s-2002-25053

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2002; 127(15): 809-814
DOI: 10.1055/s-2002-25053

Übersichten

Infektionen durch Bacillus anthracis

Infections by Bacillus anthracis W. Biederbick^1, ² , R. Fock³ , K. Güttler² , C. Veit¹

¹Inspektion des Sanitätsdienstes, Referat I 1, Bundesministerium der Verteidigung, Bonn
²Institut für Pharmakologie (Leiter: Prof. Dr. Schömig), Klinikum der Universität Köln
³Fachgruppe Seuchenschutz, Robert Koch-Institut, Berlin

Abstract

Full Text

References

Literatur

1 Barnard J P, Friedlander A M. Vaccination against Anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect Immun. 1999; 67 562-567
2 Bortolussi R, Kennedy W. Anthrax. London: Mosby In: Armstrong D, Cohen J, editors. Infectious diseases. 1st ed 1999: 8.15.7-9
3 Christopher G W, Cieslak T J, Pavlin J A, Eitzen E M. Biological warfare: a historic perspective. JAMA. 1997; 278 412-417
4 Davies J C. A major epidemic of anthrax in Zimbabwe. Cent Afr J Med (Zimbabwe). 1982; 28 291-298
5 Demicheli V, Rivetti D, Decks J J, Jefferson T, Pratt M. The effectiveness and safety of vaccines against human anthrax: a systematic review. Vaccine. 1998; 16 880-884
6 Dixon T C, Meselson M, Guillemin J, Hanna P C. Anthrax. N Engl J Med. 1999; 341 815-826
7 Eitzen E. Anthrax. Frederick, Maryland: US Army Medical Research Institute of Infectious Diseases In: Eitzen E, Pavlin C, editors. Medical Management of Biological Casualties Handbook 2nd ed 1996: 16-22
8 Fellows P F, Linscott M K, Ivins B E. et al . Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenges by Bacillus anthracis isolates of diverse geographical origin. Vaccine. 2001; 19 3241-3247
9 Friedlander A M, Welkos S L, Pitt M L. et al . Postexposure prophylaxis against experimental inhalation anthrax. J Infec Dis. 1993; 167 1239-1243
10 Friedlander A M. Anthrax. Washington: TMM Publications In: Sidell FR, Takafuji ET, Franz DR, editors. Medical aspects of chemical and biological warfare. 1st ed 1997: 467-478
11 Inglesby T V, Henderson D A, Bartlett J G. et al . Anthrax as a biological weapon. JAMA. 1999; 281 1735-1745
12 Ivins B E, Pitt M L, Fellows P F. et al . Comparative efficacy of experimental anthrax vaccine canidates against inhalational anthrax in rhesus macaques. Vaccine. 1998; 16 1141-1148
13 Kim H L, Jun W B, Lee S H, Roo M H. CT and MR findings of anthrax menigoencephalitis: report of two cases and review of the literature. Am J Neuroradiol. 2001; 22 1303-1305
14 Leppla S H. A dominant-negative therapy for anthrax. Nature Med. 2001; 7 659-660
15 Little S F, Ivins B E, Fellows P F, Friedlander A M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun. 1997; 65 5171-5175
16 Little S F, Ivins B E. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect. 1999; 1 131-139
17 Morgan M F. Anthrax - an old disease returns as a bioterrorism weapon. New Jersey Med. 2000; 97 35-41
18 Morris K. US anthrax-vaccine producer saved for now. Lancet. 1998; 351 657
19 N.N. - Centers for Disease Control and Prevention . Update: adverse effects associated with anthrax prophylaxis among postal employees - New Jersey, New York City, and the District of Columbia Metropolitan Area. MMWR. 2001; 50 1051-1054
20 N.N. - Centers for Disease Control and Prevention . Investigation of bioterrorism-related anthrax- Connecticut, 2001. MMWR. 2001; 50 1077-1079
21 N.N. - Centers for Disease Control and Prevention . Additional options for preventive treatment for persons exposed to inhalational anthrax. MMWR. 2001; 50 1142-1151
22 N.N. - Centers for Disease Control and Prevention . Evaluation of postexposure antibiotic prophylaxis to prevent anthrax. MMWR. 2002; 51 59
23 Olsnes S, Wesche J. Fighting anthrax with a mutant toxin. Science. 2001; 292 647-648
24 Pomerantsev A P, Staritsin N A, Mockov Y V, Marinin L I. Expression of cerolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine. 1997; 15 1846-1850
25 Price B M, Liner A L, Park S, Leppla S H, Mateczum A, Galloway D R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun. 2001; 69 4509-4515
26 Schnitzler N. Meldepflichtige Krankheiten. Stuttgart, Berlin, Köln: Verlag W. Kohlhammer GmbH In: Bales S, Baumann HG, editors. Infektionsschutzgesetz. 1st ed 2001: 41-58
27 Sellmann B R, Mourez M, Collier R J. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science. 2001; 292 695-697
28 Shin S, Kim Y -B, Hur G -H. Involvement of phosphlipase A2 activation in anthrax lethal toxin-induced cytotoxicity. Cell Biol Toxicol. 1999; 15 19-29
29 Shin S, Hur G -H, Kim Y -B. et al . Intracellular calcium antagonist protects cultured peritoneal macrophages against anthrax lethal toxin-induced cytotoxicity. Cell Biol Toxicol. 2000; 16 137-144
30 Shlyakhov E N, Rubinstein E, Novikov I. Anthrax post-vaccinal cell-mediated immunity in humans: kinetic pattern. Vaccine. 1997; 15 631-636
31 Shlyakhov E N, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine. 1994; 12 727-730
32 Sirard J C, Guidi-Rontani C, Fouet A, Mock M. Characterization of a plasmid region involved in Bacillus anthracis toxin production and pathogenesis. Int J Med Microbiol. 2000; 290 313-316
33 Theisohn M, Biederbick W, Rump A FE. Therapeutisches Arzneimittelmonitoring. Zülpich: Biermann Verlag GmbH In: Hummerich W, Keller R, Schrappe M editors. Klinischer Leitfaden durch das Labor - Innere Medizin. 2nd ed 1997: 426-427
34 Turnbull P CB, Broster M G, Carman J A, Manchee R J, Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infection Immunity. 1986; 52 356-363
35 Turnbull P CB, Leppla S H, Broster M G, Quinn C P, Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol. 1988; 177 292-303
36 Turnbull P CB. Bacillus. Galveston: Univ Texas Medical Branch In: Baron S, editor. Medical microbiology. 4th ed 1996: 233-245

Korrespondenz

Dr. med. Walter Biederbick

Bundesministerium der Verteidigung, InSan I 1

Postfach 1328

53003 Bonn

Phone: 0228/126247

Fax: 0228/127546

Email: walterbiederbick@bmvg.bund400.de